References

F
Fraser H, Martin NK, Brummer-Korvenkontio H, et al. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe. J Hepatol. 2018;68(3):402-411.
Fraser H, Zibbell J, Hoerger T, et al. Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic. Addiction. 2018;113(1):173-182. doi:10.1111/add.13948.
Friebus-Kardash J, Gackler A, Kribben A, et al. Successful early sofosbuvir-based antiviral treatment after transplantation of kidneys from HCV-viremic donors into HCV-negative recipients. Transpl Infect Dis. 2019;21:e13146.
Frimpong JA, D'Aunno T, Jiang L. Determinants of the availability of hepatitis C testing services in opioid treatment programs: results from a national study. Am J Public Health. 2014;104(6):e75-e82.
Frimpong JA. Missed opportunities for hepatitis C testing in opioid treatment programs. Am J Public Health. 2013;103(6):1028-1030.
Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949-958.
G
Gambotti L, Batisse D, Colin-de-Verdiere N, et al. Acute hepatitis C infection in HIV positive men who have sex with men in Paris, France, 2001-2004. Euro Surveill. 2005;10(5):115-117.
Gamkrelidze I, Pawlotsky JM, Lazarus JV, et al. Progress towards hepatitis C virus elimination in high-income countries: An updated analysis. Liver Int. 2021;41(3):456-463.
Gandhi Y, Adamczyk R, Wang R, et al. Assessment of drug-drug interactions between daclatasvir and darunavir/ritonavir or lopinavir/ritonavir. Presented at 16th International Workshop on Clinical Pharmacology of HIV and Hepatitis Therapy; May 26-28, 2015; Washington DC. 2015.
Gane E, Lawitz E, Pugatch D, et al. Glecaprevir and pibrentasvir in patients with HCV and severe renal impairment. N Engl J Med. 2017;377(15):1448-1455.
Gane EJ, Shiffman ML, Etzkorn K, et al, et al. Sofosbuvir-velpatasvir with ribavirin for 24 weeks in hepatitis C virus patients previously treated with a direct-acting antiviral regimen. Hepatology. 2017;66(4):1083-1089.
Gane EJ, Shiffman ML, Etzkorn K, et al. Sofosbuvir/Velpatasvir in Combination With Ribavirin for 24 Weeks Is Effective Retreatment for Patients Who Failed Prior NS5A-Containing DAA Regimens: Results of the Retreatment Study. In: 51st Annual Meeting of the European Association for the Study of the Liver (EASL). April 13-17. 51st Annual Meeting of the European Association for the Study of the Liver (EASL). April 13-17. Barcelona, Spain; 2016.
Gane EJ, Hyland RH, An D, et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology. 2015;149(6):1454-1461.
Garazzino S, Calitri C, Versace A, et al. Natural history of vertically acquired HCV infection and associated autoimmune phenomena. Eur J Pediatr. 2014;173:1025-1031.
Garcia-Bengoechea M, Basaras M, Barrio J, et al. Late disappearance of hepatitis C virus RNA from peripheral blood mononuclear cells in patients with chronic hepatitis C in sustained response after alpha-interferon therapy. Am J Gastroenterol. 1999;94(7):1902-1905.
Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W, Diseases practiceguidelines, Gastroenterology practiceparameters. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology. 2007;46(3):922-938.
Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the Study of Liver Diseases. Hepatology. 2017;65(1):310-335. doi:10.1002/hep.28906.
Garimella T, You X, Wang R, et al. A review of daclatasvir drug-drug interactions. Adv Ther. 2016;33(11):1867-1884.
Garimella T, Wang R, Luo WL, Luo WL. Single-dose pharmacokinetics and safety of daclatasvir in subjects with renal function impairment. Antivir Ther. 2015;20(5):535-543.
Garrison KL, German P, Mogalian E, Mathias A. The drug-drug interaction potential of antiviral agents for the treatment of chronic hepatitis C infection. Drug Metab Dispos. 2018;46(8):1212-1225.
Top